NASD · Healthcare · Diagnostics & Research · USA
Neogenomics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Diagnostics & Research industry.
NeoGenomics operates cancer-focused laboratories across the United States and United Kingdom, offering diagnostic testing and expert interpretation services. The company provides specialized pathology testing including chromosomal analysis, genetic sequencing, cell characterization, tissue staining, and residual disease detection. Its customer base comprises pathology practices, hospital labs, academic institutions, and pharmaceutical firms.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Neogenomics Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: not even its current assets cover what it owes.
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
23 more in this industry show a wider margin of safety.
We do not publish a verdict on NEO yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.